I need to check the substantive disclosure content and determine if it meets the 150-word threshold. The substantive content here is primarily the press release reference: Piclidenoson demonstrates up to 80% improvement in a kidney disease marker in a Lowe Syndrome preclinical study, published in a Nature Portfolio Journal, with the 6-K filed on November 12, 2026. The incorporated exhibit (99.1) is referenced but not provided in full text. The filing text itself (excluding boilerplate, cover, signatures, legends) contains enough substantive disclosure to proceed - the headline of the press release and the filing event itself constitute the core disclosure. Now let me check the ticker: The filing does not list a registered-securities table with exchange and ticker symbol in the standard cover format for a 6-K. The reference ticker is NYSE:CANF. I cannot confirm the exchange/ticker from the filing text itself, so per Rule 4, I should not state a ticker not written in the source text. The filing does not contain "NYSE" or "CANF" or any ticker/exchange notation. I will omit the ticker/exchange notation from the article.

Can-Fite BioPharma Ltd. filed a Form 6-K on November 12, 2026, announcing that its drug candidate Piclidenoson demonstrated up to 80% improvement in a kidney disease marker in a Lowe Syndrome preclinical study, with findings published in a Nature Portfolio Journal.

Key Highlights

  • Up to 80% improvement: Piclidenoson demonstrated up to 80% improvement in a kidney disease marker, according to the press release incorporated in the filing.
  • Lowe Syndrome preclinical study: The results are from a preclinical study focused on Lowe Syndrome, a rare kidney-affecting condition.
  • Nature Portfolio Journal publication: The study findings were published in a Nature Portfolio Journal, as stated in the filing.
  • Press release date: Can-Fite BioPharma Ltd. issued the press release on November 12, 2026.
  • Registration statement incorporation: The first, second, fourth, fifth, and sixth paragraphs of the press release are incorporated by reference into the registrant's Form S-8 and Form F-3 registration statements.

Can-Fite Reports Piclidenoson Preclinical Findings in Lowe Syndrome

Can-Fite BioPharma Ltd. submitted a Form 6-K to the U.S. Securities and Exchange Commission for the month of November 2026, disclosing a press release titled "Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal." According to the filing, the press release was dated November 12, 2026, and is furnished as Exhibit 99.1.

The filing states that specific paragraphs of the press release, described as the first, second, fourth, fifth, and sixth paragraphs, are incorporated by reference into the registrant's existing Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-236064, 333-276000, 333-281872, 333-262055, 333-294760, 333-298625, and 333-299160). The filing specifies this incorporation is effective from the date the report was submitted, "to the extent not superseded by documents or reports subsequently filed or furnished."

The 6-K was signed by Motti Farbstein, identified in the filing as Chief Executive Officer and Chief Financial Officer of Can-Fite BioPharma Ltd., on November 12, 2026. The company is headquartered at 26 Ben Gurion Street, Ramat Gan 5257346, Israel, and files annual reports under Form 20-F, as indicated on the cover page of this report.

What Was Disclosed

Can-Fite BioPharma Ltd. filed a Form 6-K disclosing a press release reporting that Piclidenoson showed up to 80% improvement in a kidney disease marker in a Lowe Syndrome preclinical study published in a Nature Portfolio Journal, with selected paragraphs incorporated into existing registration statements.